Head-To-Head Survey: Opus Genetics (NASDAQ:IRD) and Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Atara Biotherapeutics and Opus Genetics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1	1	1	1	2.50
Opus Genetics	1	1	15	1	2.89

Atara Biotherapeutics presently has a consensus target price of $9.50, indicating a potential upside of 12.43%. Opus Genetics has a consensus target price of $11.92, indicating a potential upside of 145.58%. Given Opus Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Atara Biotherapeutics.

Valuation & Earnings

This table compares Atara Biotherapeutics and Opus Genetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77 million	0.70	$32.69 million	($1.18)	-7.16
Opus Genetics	$14.20 million	28.26	-$49.59 million	($1.35)	-3.60

Atara Biotherapeutics has higher revenue and earnings than Opus Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Atara Biotherapeutics and Opus Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Institutional & Insider Ownership

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Atara Biotherapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Summary

Atara Biotherapeutics beats Opus Genetics on 8 of the 14 factors compared between the two stocks.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.